Welcome to our dedicated page for Rani Therapeutics Holdings SEC filings (Ticker: RANI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rani Therapeutics Holdings, Inc. filings document the regulatory record of a clinical-stage biotherapeutics company developing oral delivery technology for biologics and drugs. Form 8-K reports include quarterly and annual financial results, corporate updates, clinical and preclinical program disclosures, collaboration and license matters, and material agreements affecting the company’s operations and strategy.
The filing record also covers capital-structure activity involving Class A common stock, common warrants and pre-funded warrants, as well as Nasdaq continued-listing compliance notices. Proxy materials describe annual meeting matters, board elections, auditor ratification, governance procedures and stockholder voting mechanics for RANI’s public-company structure.
RA Capital Management, L.P. and affiliated entities report beneficial ownership in Rani Therapeutics Holdings, Inc. Class A common stock as of June 30, 2026. RA Capital Healthcare Fund, L.P. directly holds 8,500,000 Class A shares, pre-funded warrants exercisable for up to 16,500,000 shares, and common warrants exercisable for up to 25,000,000 shares. Both warrant series contain Beneficial Ownership Blockers that prevent exercises which would raise ownership above 9.99% of Class A shares outstanding, limiting current exercisability so that beneficial ownership does not exceed 11,530,414 shares. Based on outstanding and recently issued shares cited from the issuer’s reports and including 3,030,414 shares issuable upon warrant exercise, each reporting person’s beneficial ownership percentage was 9.99%, shown as 9.9% on the cover pages due to EDGAR field rounding. Voting and dispositive power over the Fund’s holdings is delegated to RA Capital, with various reporting persons disclaiming beneficial ownership except for Section 13(d) purposes.
Rani Therapeutics Holdings, Inc. reported for the period ended June 30, 2026 that it remains a clinical-stage company developing its RaniPill oral biologics platform, with two configurations, RaniPill GO and high‑capacity RaniPill HC. Contract revenue reached $1.7 million in the quarter and $3.4 million year‑to‑date, primarily from a Chugai collaboration, compared with minimal revenue a year earlier. Operating expenses were $10.5 million for the quarter and $20.6 million for the first six months.
Net loss was $8.4 million for the quarter and $16.4 million year‑to‑date. Cash, cash equivalents and marketable securities totaled $53.4 million, and the company states this should fund operations for at least twelve months from issuance of these financial statements. In May 2026 it raised $20.0 million gross through a Class A share and pre‑funded warrant financing. Rani continues its RT‑114 obesity program with ProGen and reported Phase 1a data showing RT‑114 oral delivery achieved bioavailability exceeding 150% versus a matched subcutaneous dose.
Rani Therapeutics Holdings, Inc. reported second quarter 2026 results and a corporate update. The company highlighted positive initial Phase 1a data for RT-114, an orally administered RaniPill Capsule delivering PG-102, showing oral bioavailability greater than 150% relative to matched subcutaneous dosing, with no serious adverse events and no events attributed to the RaniPill Capsule.
Rani completed a $20 million registered direct offering led by a sovereign wealth fund, entered a new obesity and metabolic disease collaboration with PegBio, and appointed Nicholas Maestas as Chief Financial Officer and Michelle Gilson to the Board. Cash, cash equivalents and marketable securities totaled $53.4 million as of June 30, 2026, and the company expects this to fund operations at least through 2027. For the quarter, contract revenue was $1.7 million versus none a year earlier, research and development expenses were $5.0 million, general and administrative expenses were $5.5 million, and net loss was $8.4 million compared with $11.2 million in 2025.
Rani Therapeutics Holdings, Inc. director Michelle Gilson received a grant of 247,200 Director Stock Options on 2026-08-03, each for one share of Class A Common Stock at an exercise price of 0.8013 per share, expiring on 2036-08-02.
The options vest over three years: 1/3 on the first anniversary of the grant date and 1/36 monthly thereafter, subject to Continuous Service under the company’s 2021 Equity Incentive Plan, or in full upon a Change in Control. Following this award, Gilson holds 247,200 options directly.
Michelle Gilson, a director of Rani Therapeutics Holdings, Inc., reports beneficial ownership of a stock option covering 12,500 shares of Class A Common Stock. The option has an exercise price of $7.46 per share, expires on October 30, 2026, is fully vested and exercisable, and is held directly.
Rani Therapeutics Holdings, Inc. appointed Michelle Gilson to its Board of Directors on August 1, 2026, and named her chair of the Audit Committee, with her term running until the earlier of the next annual meeting of stockholders, the qualification of a successor, or her death, resignation, or removal.
Gilson, age 34, is the former Chief Financial Officer of Arcellx, Inc., serving from May 2022 through its acquisition by Gilead Sciences, Inc. in April 2026, and previously held biotechnology equity research and investment banking roles at several financial firms. She will serve as a non-employee director and receive compensation under the company’s Non-Employee Director Compensation Policy and will enter into the company’s standard indemnification agreement. The company states there are no arrangements or understandings regarding her appointment, no family relationships with other directors or executive officers, and no transactions requiring disclosure under Item 404(a) of Regulation S-K.
Vanguard Capital Management reported its holdings of Rani Therapeutics Holdings Inc common stock, beneficially owning 5,052,862 shares, representing 4.49% of the class as of June 30, 2026. These securities have CUSIP 753018100.
Vanguard has sole voting power over 489,877 shares and sole dispositive power over 5,052,862 shares, with no shared voting or dispositive power. The holdings include securities managed by Vanguard Capital Management LLC and certain affiliated entities and business divisions, including Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC, and Vanguard Investments Australia Ltd.
The report notes that the position reflects securities held by Vanguard funds and client accounts over which these entities exercise voting and/or dispositive power. Interests of other persons in these securities are each below 5% of the class. The filing is signed by an authorized signatory, Head of Global Fund Administration, on July 31, 2026.
Imran Mir A, a director and 10% owner of Rani Therapeutics Holdings, Inc., purchased 36,000 shares of Class A Common Stock on July 21, 2026 at a weighted average price of about $0.69 per share, in multiple transactions between $0.688 and $0.69. After this purchase, he directly holds 2,119,334 Class A shares and has indirect interests in 74,139 Class A and 22,660,053 Class B shares through affiliated entities, for which he disclaims beneficial ownership beyond his pecuniary interest.
Rani Therapeutics Holdings, Inc. Chief Technical Officer Alireza Javadi reported two dispositions of Class A Common Stock related to restricted stock unit settlements. On March 27, 2026, he sold 386 shares at $0.78 per share to cover tax withholding obligations. On June 27, 2026, 309 shares at $0.74 per share were withheld and surrendered to the issuer to satisfy tax withholding obligations. Both transactions were reported late due to inadvertent administrative oversight.
Rani Therapeutics Holdings, Inc. director and Chief Executive Officer Imran Talat purchased 35,000 shares of Class A Common Stock on July 17, 2026 at $0.7198 per share in an open-market transaction, bringing his direct holdings to 469,736 shares. This total includes 12,343 shares held by VH Moll, L.P., for which he disclaims beneficial ownership except to the extent of his pecuniary interest. The Rule 10b5-1 trading-plan checkbox is unchecked.